Evidence map›Paper›PMID 38354187›Full record

ArticlePLOS global public health2024

Improved vaccination coverage after two rounds of multi-antigenic catch-up vaccination in Mauritania.

Maider Pagola-Ugarte, Ankur Rakesh, Julita Gil-Cuesta, David Kidinda, Thierno Moctar Kelly, Sidi Zahaf, Mohamed Mahmoud O Ely Mahmoud, Mohamedou O Mohamed Salem, Mbareck Houmeid, Dah Cheikh and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Maider Pagola-UgarteLuxembourg Operational Research Unit (LuxOR), Médecins Sans Frontières Luxembourg, Luxembourg.ORCID https://orcid.org/0000-0002-5081-3347
Ankur RakeshLuxembourg Operational Research Unit (LuxOR), Médecins Sans Frontières Luxembourg, Luxembourg.
Julita Gil-CuestaLuxembourg Operational Research Unit (LuxOR), Médecins Sans Frontières Luxembourg, Luxembourg.
David KidindaMédecins Sans Frontières, Mauritania.
Thierno Moctar KellyMédecins Sans Frontières, Mauritania.
Sidi ZahafMinistry of Health, Mauritania.
Mohamed Mahmoud O Ely MahmoudMinistry of Health, Mauritania.
Mohamedou O Mohamed SalemDepartment of Expanded Programme of Immunisation, Ministry of Health, Mauritania.
Mbareck HoumeidDepartment of Expanded Programme of Immunisation, Ministry of Health, Mauritania.
Dah CheikhAMP Health, Mauritania.
Naceredine OuldzeidouneWorld Health Organisation, Mauritania.
Catherine BachyMédecins Sans Frontières, Operational Centre of Brussels, Belgium.ORCID https://orcid.org/0000-0003-2786-9219
Médecins Sans Frontières · LULebanese International University of Mauritania · MRMédecins Sans Frontières · BE

Funding

World Health Organization 001
6 · The paper itself

Abstract

Although Mauritania carried out its Expanded Programme on Immunization (EPI), in 2015 the goal of vaccination coverage (VC) remained unmet in Bassikounou district and Mbera camp, contexts with large migrant populations. In response, during 2018, the national authorities, together with Médecins Sans Frontières organised two rounds of multi-antigenic mass vaccination campaigns (2RMASVC). The campaigns included oral polio (OPV), pneumococcal (PCV13), pentavalent and rotavirus vaccines for all eligible children six weeks to 59 months old. This study describes the results of the 2RMASVC. Cross-sectional household VC surveys (VCS1 and VCS2) were conducted before and after the 2RMASVC. Data were collected on vaccination status according to self-reporting and vaccination cards, and on reasons for non-vaccination (RNV). In total, 4,569 children received at least one dose of vaccine in the first round and 5,602 children in the second. Baseline VC, as fully vaccinated, according to VCS1, was 59.9% of children 12 to 59 months in Bassikounou district and 65.8% in Mbera camp. After the 2RMASVC, the coverages increased to 84.7% and 75.9% respectively. Absence from home, lack of motivation, late initiation of vaccinations and lack of awareness about vaccination were the main RNV during the 2RMASVC. Although the 2RMASVC did not reach its goal of 90%-95% VC, the strategy significantly increased VC in the two settings for children aged 12 to 59 months. Therefore, this catch-up approach could be considered to improve VC of children who miss out of the EPI strategy in resource-limited settings.

Identifiers

PMID38354187
PMCPMC10866457
OpenAlexW4391808023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.